When leaders at Exact Sciences discussed dealing with the adversity of cold weather and a “historically severe” flu season in early 2018, some industry observers predicted a potential break in the long growth streak of the Madison, WI-based company’s flagship product, a stool-based DNA test for colorectal cancer known as Cologuard.
But on Thursday, Exact (NASDAQ: EXAS) said it completed 186,000 Cologuard tests during the three-month period ending March 31. The quarterly total beat the company’s projection in February that it would complete between 176,000 and 181,000 Cologuard tests in the first quarter.
Exact develops diagnostic tests for several types… Read more »
UNDERWRITERS AND PARTNERS